Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ZYNE
  • CUSIP: N/A
  • Web: www.zynerba.com
Capitalization:
  • Market Cap: $123.56 million
  • Outstanding Shares: 13,257,000
Average Prices:
  • 50 Day Moving Avg: $8.02
  • 200 Day Moving Avg: $8.02
  • 52 Week Range: $5.42 - $25.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.05
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.37 per share
  • Price / Book: 1.75
Profitability:
  • EBITDA: ($28,660,000.00)
  • Return on Equity: -54.35%
  • Return on Assets: -48.11%
Debt:
  • Current Ratio: 9.73%
  • Quick Ratio: 9.73%
Misc:
  • Average Volume: 1.21 million shs.
  • Beta: 5.46
  • Short Ratio: 5.78
 

Frequently Asked Questions for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its earnings results on Tuesday, August, 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.04. View Zynerba Pharmaceuticals' Earnings History.

Where is Zynerba Pharmaceuticals' stock going? Where will Zynerba Pharmaceuticals' stock price be in 2017?

9 analysts have issued 1-year target prices for Zynerba Pharmaceuticals' stock. Their forecasts range from $7.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $14.63 in the next year. View Analyst Ratings for Zynerba Pharmaceuticals.

What are analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (10/18/2017)
  • 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
  • 3. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)

Who are some of Zynerba Pharmaceuticals' key competitors?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:

  • Armando Anido, Chairman of the Board, Chief Executive Officer
  • Terri B. Sebree, President
  • James E. Fickenscher, Chief Financial Officer, Vice President - Corporate Development
  • Suzanne M. Hanlon, Secretary, General Counsel and Vice President, Human Resources
  • William Roberts, Vice President - Investor Relations and Corporate Communications
  • Ray Mannion, Vice President - Manufacturing
  • Brian Rosenberger, Vice President - Commercial
  • Warren D. Cooper M.D., Lead Independent Director
  • William J. Federici, Independent Director
  • Thomas L. Harrison, Independent Director

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

How do I buy Zynerba Pharmaceuticals stock?

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $9.39.


MarketBeat Community Rating for Zynerba Pharmaceuticals (NASDAQ ZYNE)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $14.63 (55.75% upside)
Consensus Price Target History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Price Target History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/1/2017Roth CapitalSet Price TargetBuy$15.00MediumView Rating Details
10/2/2017Cantor FitzgeraldUpgradeNeutral -> Overweight$4.00 -> $17.00LowView Rating Details
9/29/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
9/29/2017Canaccord GenuityBoost Price TargetBuy$9.00 -> $15.00HighView Rating Details
9/28/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$7.00 -> $16.00HighView Rating Details
8/15/2017CIBCReiterated RatingOutperform -> Market PerformLowView Rating Details
8/15/2017HC WainwrightSet Price TargetHold$7.00LowView Rating Details
8/15/2017Jefferies Group LLCDowngradeBuy -> Hold$12.00 -> $7.00LowView Rating Details
8/14/2017Maxim GroupReiterated RatingHoldHighView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Earnings by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Earnings History by Quarter for Zynerba Pharmaceuticals (NASDAQ ZYNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017Q2 2017($0.60)($0.64)$0.38 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.55)($0.60)$0.07 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.75)($0.71)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.69)($0.67)$0.20 millionViewN/AView Earnings Details
8/11/2016Q2($0.53)($0.70)$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)$0.03 million$0.01 millionViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)$0.20 million$0.05 millionViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)$0.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
2017 EPS Consensus Estimate: ($2.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.50)($0.56)
Q2 20173($0.62)($0.51)($0.57)
Q3 20173($0.64)($0.42)($0.56)
Q4 20173($0.66)($0.45)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Ownership Percentage: 10.02%
Institutional Ownership Percentage: 34.32%
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Armando AnidoChairmanBuy5,000$19.70$98,500.00View SEC Filing  
5/12/2017James E FickenscherCFOBuy5,200$19.82$103,064.00View SEC Filing  
12/29/2016Michael RappMajor ShareholderBuy10,000$15.85$158,500.00View SEC Filing  
12/7/2016James E FickenscherCFOBuy7,000$14.08$98,560.00View SEC Filing  
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Latest Headlines for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Source:
DateHeadline
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 18 at 8:58 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - October 14 at 5:16 PM
finance.yahoo.com logoLike a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week
finance.yahoo.com - October 12 at 10:37 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 4:42 PM
benzinga.com logoBenzinga's Top Upgrades, Downgrades For October 2, 2017 - Benzinga
www.benzinga.com - October 3 at 4:42 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Given a $15.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - October 2 at 3:14 PM
benzinga.com logo5 Stocks To Watch For September 29, 2017 - Benzinga
www.benzinga.com - October 1 at 6:44 AM
benzinga.com logoZynerba's Recent Results Revitalize The Bull Case, But Risks Remain
www.benzinga.com - September 30 at 10:52 AM
reuters.com logoZynerba's stock on a high as cannabis-based drug succeeds in trial - Reuters
www.reuters.com - September 29 at 10:37 PM
thestreet.com logoZynerba Pharmaceuticals Reaches Analyst Target Price
www.thestreet.com - September 29 at 5:35 PM
reuters.com logoBRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study
www.reuters.com - September 29 at 5:35 PM
investopedia.com logoZynerba Stock: Where Is It Headed From Here?
www.investopedia.com - September 29 at 5:35 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Given "Hold" Rating at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 29 at 5:28 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - September 29 at 4:40 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Price Target Raised to $15.00 at Canaccord Genuity
www.americanbankingnews.com - September 29 at 10:56 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Raised to Overweight at Piper Jaffray Companies
www.americanbankingnews.com - September 28 at 11:28 PM
thestreet.com logoNotable Thursday Option Activity: ZYNE, EPC, RDI
www.thestreet.com - September 28 at 12:51 PM
globenewswire.com logoZynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
globenewswire.com - September 28 at 12:51 PM
247wallst.com logoZynerba Pharma Wins Big on Cannabis Trial
247wallst.com - September 28 at 12:51 PM
reuters.com logoZynerba's stock on a high as cannabis-based drug succeeds in trial
www.reuters.com - September 28 at 12:50 PM
americanbankingnews.com logoShort Interest in Zynerba Pharmaceuticals, Inc. (ZYNE) Declines By 25.0%
www.americanbankingnews.com - September 17 at 1:20 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 16 at 4:54 PM
americanbankingnews.com logoZynerba Pharmaceuticals (ZYNE) vs. Its Rivals Financial Contrast
www.americanbankingnews.com - September 14 at 2:22 AM
globenewswire.com logoZynerba Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 3:19 PM
finance.yahoo.com logoZynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 6 at 3:19 PM
benzinga.com logoNemus Bioscience CEO Talks 'Waves Of Dominance' In The Cannabis Therapeutics Industry - Benzinga
www.benzinga.com - September 5 at 3:40 PM
finance.yahoo.com logo2 Marijuana Stocks That Have Imploded Since August Began
finance.yahoo.com - August 23 at 2:26 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 22 at 4:36 PM
americanbankingnews.com logoCanaccord Genuity Analysts Give Zynerba Pharmaceuticals, Inc. (ZYNE) a $9.00 Price Target
www.americanbankingnews.com - August 18 at 3:14 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Forecasted to Post FY2019 Earnings of ($1.59) Per Share
www.americanbankingnews.com - August 17 at 3:38 PM
americanbankingnews.com logoJefferies Group LLC Downgrades Zynerba Pharmaceuticals, Inc. (ZYNE) to Hold
www.americanbankingnews.com - August 15 at 8:02 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 15 at 6:40 PM
rttnews.com logoZynerba Pharmaceuticals Inc. (ZYNE) Has Tumbled To A New Low On Study Results
www.rttnews.com - August 15 at 4:16 PM
finance.yahoo.com logoZynerba Midstage Cannabinoid Trial Falls Short
finance.yahoo.com - August 15 at 4:16 PM
americanbankingnews.com logoZynerba Pharmaceuticals' (ZYNE) "Market Perform" Rating Reiterated at CIBC
www.americanbankingnews.com - August 15 at 2:26 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Upgraded to "Buy" by Roth Capital
www.americanbankingnews.com - August 15 at 1:06 PM
globenewswire.com logoZynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 8:42 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) PT Set at $4.00 by Cantor Fitzgerald
www.americanbankingnews.com - August 14 at 1:06 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Rating Reiterated by Maxim Group
www.americanbankingnews.com - August 14 at 1:06 PM
finance.yahoo.com logoZynerba Pharmaceuticals Upcoming Catalysts and Price Targets
finance.yahoo.com - August 14 at 8:42 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Zynerba Pharmaceuticals (ZYNE) Stock?
finance.yahoo.com - August 11 at 9:26 AM
finance.yahoo.com logoPharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure
finance.yahoo.com - August 11 at 9:26 AM
americanbankingnews.com logoCantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)
www.americanbankingnews.com - August 10 at 12:10 PM
americanbankingnews.com logoJefferies Group Research Analysts Reduce Earnings Estimates for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)
www.americanbankingnews.com - August 10 at 12:10 PM
americanbankingnews.com logoZynerba Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ZYNE)
www.americanbankingnews.com - August 10 at 8:06 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for Zynerba Pharmaceuticals, Inc. (ZYNE)
www.americanbankingnews.com - August 9 at 9:44 PM
benzinga.com logoIs GW Pharma Now The Future Of Cannabis-Based Drugs? - Benzinga
www.benzinga.com - August 9 at 8:37 PM
nasdaq.com logoZynerba Pharmaceuticals Inc. (ZYNE) Is Sinking After Phase 2 Study Fails
www.nasdaq.com - August 9 at 9:31 AM
americanbankingnews.com logoOppenheimer Holdings Weighs in on Zynerba Pharmaceuticals, Inc.'s Q3 2017 Earnings (ZYNE)
www.americanbankingnews.com - August 9 at 7:26 AM
americanbankingnews.com logoCantor Fitzgerald Reiterates Overweight Rating for Zynerba Pharmaceuticals, Inc. (ZYNE)
www.americanbankingnews.com - August 8 at 8:56 PM

Social

Chart

Zynerba Pharmaceuticals (ZYNE) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.